TTrialPathMatch Me to Trials
← Back to trials
RecruitingHot FlashesBreast Cancer

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Eligible age

18+ yrs

Accepts

Women

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).

Sponsor: University of Arkansas

You may qualify if…

  • ✓ Women with a history of invasive breast cancer or DCIS
  • ✓ Currently taking aromatase inhibitors or tamoxifen
  • ✓ Not receiving hormone replacement therapy for minimum of one month
  • ✓ Age 18 years or older
  • ✓ Self-reported hot flashes at least fourteen times per week
  • ✓ Self-reported hot flashes for at least one month
  • ✓ If receiving non-tricyclic antidepressants (venlafaxine, paroxetine, citalopram, sertraline, etc.) or gabapentin, no change in regimen in past 4 weeks.

You may not qualify if…

  • ✕ Receiving any other treatment for hot flashes within the past month, including estrogens, progestins, androgens, or gabapentin.
  • ✕ Current use of clonidine or solifenacin. (If patients have been off of these for one month, then they are eligible)
  • ✕ History of severe renal or moderate or severe hepatic impairment, as indicated by physical exam and medical record
  • ✕ Concurrent or planned chemotherapy or radiotherapy (within next 3 months)
  • ✕ Currently receiving tricyclic antidepressants, monoamine oxidase inhibitors, barbiturates, pimozide.
  • ✕ Currently using CYP3A4 inducers (i.e., aminoglutethimide, carbamazepine, dexamethasone, efavirenz, ethosuximide, griseofulvin, modafinil, nafcillin, nevirapine, oxcarbazepine, phenobarbital, phenylbutazone, phenytoin, primidone, rifabutin, rifampin, rifapentine, St. John's Wort, sulfadimidine, sulfinpyrazone, troglitazone) or potent CYP3A4 inhibitors (i.e., chloramphenicol, clarithromycin, erythromycin, imatinib mesylate, indinavir sulfate, itraconazole, ketoconazole, nefazoldone, nelfinavir mesylate, ritonavir, telithromycin, troleandomycin).
  • ✕ Uncontrolled or poorly controlled narrow-angle glaucoma, urinary retention, gastric retention (evaluated from history \& physical exam and medical record)
  • ✕ Hypotension or uncontrolled hypertension (160/95 \> BP \< 100/60)

Where it's recruiting

Arkansas

Little Rock

Source: ClinicalTrials.gov · NCT01530373 · last updated 2026-03-05

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breas · TrialPath